Research progress of perioperative treatment for esophagogastric junction adenocarcinoma

doi:10.3760/cma.j.issn.1007-1245.2024.19.004

Abstract

Abstract:

The incidence of esophagogastric junction adenocarcinoma is still high in China. In recent years, surgical treatment combined with chemotherapy, radiotherapy, immunotherapy, and targeted therapy has gradually improved the prognosis of patients with gastric cancer, but there are still many controversies in the perioperative treatment. This study summarized the research progress related to perioperative treatment for esophagogastric junction adenocarcinoma, including preoperative neoadjuvant therapy, postoperative adjuvant therapy, perioperative radiotherapy, and immunotherapy, so as to clarify the current research direction.

Key words:

Esophagogastric junction adenocarcinoma, Perioperative treatment, Neoadjuvant therapy, Adjuvant therapy, Chemotherapy, , Radiotherapy, Immunotherapy, Progress

摘要：

食管胃结合部腺癌在我国的发病率仍居高不下。近年来，以手术治疗为主，联合化疗、放疗、免疫治疗、靶向治疗等综合治疗模式逐步改善了患者的预后，但围手术期治疗模式还存在不少争议。本文总结了食管胃结合部腺癌围手术期治疗相关研究进展，从术前新辅助治疗、术后辅助治疗、围手术期放疗及免疫治疗等方面进行综述，以明晰目前研究方向。

关键词:

食管胃结合部腺癌, 围手术期治疗, 新辅助治疗, 辅助治疗, 化疗, 放疗, 免疫治疗, 进展

Chen Xiaojiang, Li Yuanfang.

Research progress of perioperative treatment for esophagogastric junction adenocarcinoma [J]. International Medicine and Health Guidance News, 2024, 30(19): 3184-3188.

陈小江李元方.

食管胃结合部腺癌围手术期治疗研究进展 [J]. 国际医药卫生导报, 2024, 30(19): 3184-3188.

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022 [J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006.
[3] Arnold M, Ferlay J, van Berge Henegouwen MI, et al. Global burden of oesophageal and gastric cancer by histology and subsite in 2018 [J]. Gut, 2020, 69(9): 1564-1571. DOI: 10.1136/gutjnl-2020-321600.
[4] Nakauchi M, Walch HS, Nussenzweig S, et al. Genomic landscape of adenocarcinomas across the gastroesophageal junction: moving on from the Siewert classification [J]. Ann Surg, 2024. DOI: 10.1097/SLA.0000000000006363.
[5] 胡建昆,陈小龙. 食管胃结合部腺癌外科治疗争议、共识及进展[J]. 中国普外基础与临床杂志,2023,30(10):1153-1158. DOI:10.7507/1007-9424.202309026.
[6] Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer [J]. N Engl J Med, 1998, 339(27): 1979-1984. DOI: 10.1056/NEJM199812313392704.
[7] Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J]. N Engl J Med, 2006, 355(1): 11-20. DOI: 10.1056/NEJMoa055531.
[8] Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer [J]. J Clin Oncol, 2009, 27(30): 5062-5067. DOI: 10.1200/JCO.2009.22.2083.
[9] Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial [J]. J Clin Oncol, 2011, 29(13): 1715-1721. DOI: 10.1200/JCO.2010.33.0597.
[10] van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer [J]. N Engl J Med, 2012, 366(22): 2074-2084. DOI: 10.1056/NEJMoa1112088.
[11] Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial [J]. J Clin Oncol, 2021, 39(18): 1995-2004. DOI: 10.1200/JCO.20.03614.
[12] Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J]. Lancet, 2019, 393(10184): 1948-1957. DOI: 10.1016/S0140-6736(18)32557-1.
[13] Iwasaki Y, Terashima M, Mizusawa J, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial [J]. Gastric Cancer, 2021, 24(2): 492-502. DOI: 10.1007/s10120-020- 01136-7.
[14] Kang YK, Yook JH, Park YK, et al. PRODIGY: a phase Ⅲ study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer [J]. J Clin Oncol, 2021, 39(26): 2903-2913. DOI: 10.1200/JCO.20.02914.
[15] Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial [J]. Lancet Oncol, 2021, 22(8): 1081-1092. DOI: 10.1016/S1470-2045(21)00297-7.
[16] Wang FH, Zhang XT, Tang L, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023 [J]. Cancer Commun (Lond), 2024, 44(1): 127-172. DOI: 10.1002/cac2.12516.
[17] Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine [J]. N Engl J Med, 2007, 357(18): 1810-1820. DOI: 10.1056/NEJMoa072252.
[18] Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer [J]. J Clin Oncol, 2011, 29(33): 4387-4393. DOI: 10.1200/JCO.2011.36.5908.
[19] Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial [J]. Lancet, 2012, 379(9813): 315-321. DOI: 10.1016/S0140-6736(11)61873-4.
[20] Kakeji Y, Yoshida K, Kodera Y, et al. Three-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage Ⅲ gastric cancer: JACCRO GC-07 [J]. Gastric Cancer, 2022, 25(1):188-196. DOI: 10.1007/s10120-021-01224-2.
[21] Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction [J]. N Engl J Med, 2001, 345(10): 725-730. DOI: 10.1056/NEJMoa010187.
[22] Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection [J]. J Clin Oncol, 2012, 30(19): 2327-33. DOI: 10.1200/JCO.2011.36.7136.
[23] Lee J, Lim DH, Kim S, et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial [J]. J Clin Oncol, 2012, 30(3): 268-273. DOI: 10.1200/JCO.2011.39.1953.
[24] Park SH, Lim DH, Sohn TS, et al. A randomized phase Ⅲ trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial [J]. Ann Oncol, 2021, 32(3): 368-374. DOI: 10.1016/j.annonc.2020.11.017.
[25] Yuan SQ, Nie RC, Jin Y, et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial [J]. Nat Med, 2024, 30(2): 552-559. DOI: 10.1038/s41591-023-02721-w.
[26] Lorenzen S, Götze TO, Thuss-Patience P, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase Ⅱ/Ⅲ DANTE/IKF-s633 trial [J]. J Clin Oncol, 2024, 42(4): 410-420. DOI: 10.1200/JCO.23.00975.
[27] Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study [J]. Lancet Oncol, 2024, 25(2): 212-224. DOI: 10.1016/S1470-2045(23)00541-7.
[28] Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer [J]. N Engl J Med, 2021, 384(13): 1191-1203. DOI: 10.1056/NEJMoa2032125.
[29] Kang YK, Terashima M, Kim YW, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage Ⅲ gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Gastroenterol Hepatol, 2024, 9(8): 705-717. DOI: 10.1016/S2468-1253(24)00156-0.